Tamtam Try Tamtam free
Hospital for Special Surgery logo

Hospital for Special Surgery account plan

Top-ranked orthopedic and rheumatology

At a glance

Hospital for Special Surgery (HSS) is a New York not-for-profit orthopedic and rheumatology hospital with $2,050.1 million of operating revenue in 2025.

Hospital for Special Surgery (HSS) is a not-for-profit academic hospital in Manhattan specialised in musculoskeletal care, orthopedic surgery and rheumatology, with research and graduate medical education. It performs 46,000 surgeries a year and sees more than 500,000 patients a year, and serves as the principal orthopedic and rheumatology facility for New York Presbyterian Hospital. In 2025 total operating revenue was $2,050.1 million (2024: $1,851.4 million) and the operating surplus before other items $141.2 million, with commercial payors providing $1,372.4 million of net patient service revenue. It is a Section 501(c)(3) organisation and expands through physician co-owned ambulatory surgery centers and regional collaborations.

Business units

Strategic priorities

National outpatient orthopedic platform
With General Atlantic, HSS acquired Legent Health in October 2025 to take its orthopedic and spine model nationwide through ASCs, applying its standardised clinical care pathways.
Shift to outpatient surgery
CEO Bryan Kelly says close to 80% of orthopedics is now authorised for payment as outpatient surgery, versus roughly half before COVID-19, and HSS had built or planned at least seven ASCs before the Legent deal.
Regional expansion
Beyond the main campus, HSS works through the Stamford Hospital collaboration and, from March 2026, a collaboration with Jupiter Medical Center in Florida.
Agentic AI and digital care models
Chief Digital and Technology Officer Ashis Barad aims to use AI to create new care models, starting with call-center triage, appointment scheduling, post-surgery check-ins and HR policy look-ups.
Data, outcomes and payer value
HSS cites mature clinical protocols and outcome data, and sees standardised orthopedic data as valuable to payer partners.

Investments and deals

Kellen Tower
The 12-story tower was substantially complete at December 31, 2025 and opened in early 2026; additions to property, plant and equipment were $133.4 million in 2025.
Legent Health acquisition
In October 2025 HSS partnered with General Atlantic to acquire Plano, Texas-based Legent Health, launching a national ASC platform.
ASC financing
In 2025 HSS Long Island ASC took a construction loan of up to $27.6 million and HSS Mahwah ASC borrowed $10.6 million, both guaranteed by the Hospital.
New leases
Operating lease liabilities rose to $641.8 million from $447.2 million after $210.6 million of new leases in 2025.
Implant lab and gait analysis
An in-house implant lab partners with a company to 3-D print custom implants, and markerless computer-vision gait analysis is used in joint replacement research.

Challenges and risks

Inpatient surgery economics
Kelly says the economics of inpatient surgery are becoming more challenging "Because the cost is outpacing the revenue".
Payment policy risk
The statements warn that federal and state legislation could reduce payment and enrollment rates, and Medicare cost reports are settled only through 2022.
Rising labour and supply costs
Salaries and wages rose to $896.9 million in 2025 from $835.1 million, and supplies and other to $664.3 million from $613.8 million.
Keeping quality while scaling
Dr. Michael Ast warns against a cost-cutting "race to the bottom" that would affect quality of care as the ASC model expands.
Investment and liability estimates
The statements flag valuation uncertainty on $541.7 million of alternative investments and estimates of $135.2 million of captive insurance liabilities.

What leadership says

“This is an opportunity for us to expand HSS quality care to more patients in more locations at greater convenience and greater value.”

Bryan Kelly, President and CEO · ASC News interview, April 13, 2026, on the Legent Health platform

“High-quality care starts with high-quality doctors.”

Bryan Kelly, President and CEO · ASC News interview, April 13, 2026

“I believe agentic AI is going to be the great orchestrator of healthcare.”

Ashis Barad, Chief Digital and Technology Officer · MedTech Dive interview, October 3, 2025

“I look mostly at platform companies over point solutions”

Ashis Barad, Chief Digital and Technology Officer · MedTech Dive interview, October 3, 2025, on how HSS buys technology

Where a supplier can help

AI agents for patient access
Tied to the agentic AI priority, platforms for call-center triage, scheduling and post-surgery check-ins match the use cases HSS names; it prefers platforms over point solutions with proven ROI or outcome value.
ASC rollout services
The national ASC platform and new centers on Long Island and in Mahwah create needs for surgical equipment, facility build-out and ambulatory operations software.
Outcomes data and payer analytics
HSS's goal of standardising orthopedic data across sites for payer partners points to data integration and analytics suppliers.
Cost control in a high-cost model
Rising labour and supply costs and challenging inpatient economics make supply-chain, workforce and revenue-cycle efficiency offers relevant.
Device and imaging innovation
The implant lab, gait analysis and the emerging technologies committee that reviews every vendor are entry points for 3-D printing, robotics and computer-vision suppliers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Hospital for Special Surgery?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Hospital for Special Surgery

What does Hospital for Special Surgery do?

HSS is a not-for-profit academic hospital in New York specialised in orthopedic surgery, rheumatology and musculoskeletal care, with research and medical education.

What is HSS's revenue?

Total operating revenue was $2,050.1 million in 2025, up from $1,851.4 million in 2024, with an operating surplus before other items of $141.2 million.

How large is HSS's clinical activity?

HSS performs 46,000 surgeries a year and sees more than 500,000 patients a year.

What is HSS's growth strategy?

HSS is extending its model beyond New York through ambulatory surgery centers, including a national platform launched with General Atlantic through the Legent Health acquisition, and regional collaborations in Connecticut and Florida.

Who leads HSS?

Dr. Bryan Kelly is President and CEO, and Ashis Barad is Chief Digital and Technology Officer.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)